Buy Rating on Compass Therapeutics for Breakthrough in Resistant Tumor Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report) today and set a price target of $10.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including the promising preclinical data presented by Compass Therapeutics. The data demonstrated that the combination of two of the company’s antibodies, CTX-009 and CTX-471, showed increased efficacy in fighting tumors that are negative for major histocompatibility complex class I (MHC-1). These types of tumors are known to be particularly resistant to current immuno-oncology therapies. The analyst believes that this synergy between the two antibodies could potentially lead to a significant advancement in treating such resistant tumor types.

The report also underscores the importance of this development as it could address a critical unmet medical need in oncology. Tumors that lack MHC-1 expression are typically invisible to the immune system, rendering many existing treatments ineffective. However, the combination therapy involving CTX-009 and CTX-471 appears to be capable of overcoming this challenge by re-establishing anti-tumor immunity, particularly through the mediation of natural killer (NK) cells. Pantginis’s recommendation reflects his optimism about the potential market opportunities for Compass Therapeutics, as well as the capacity for this combination therapy to become an alternative treatment for patients who have not responded to other types of immunotherapy.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Compass Therapeutics (CMPX) Company Description:

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.